Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy, at the upcoming EULAR 2025 Congress in Barcelona. FT819 targets CD19 and is being evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE) without the use of fludarabine conditioning, a significant shift from traditional CAR T-cell approaches.
The oral presentation, scheduled for June 11, will highlight FT819’s safety and efficacy in lupus patients treated with either a fludarabine-free regimen or maintenance therapy without conditioning. This approach could eliminate the need for toxic chemotherapy, potentially enabling safer, more accessible outpatient treatment for autoimmune diseases.
A biotechnologist in a lab overlooking a microscope, examining a sample of substances to test for therapeutic properties.
Fate Therapeutics, Inc. will also showcase preclinical advances in its iPSC-derived CAR T and CAR-NK cell platforms, including Sword and Shield technology and multi-antigen targeting, aimed at broadening autoimmune therapy applications. The company’s proprietary iPSC platform allows for scalable, off-the-shelf cell therapies, positioning Fate Therapeutics, Inc. as a leader in next-generation immunotherapies for autoimmune conditions.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
